Hims and Hers Health Inc vs Dr. Reddy's Laboratories Ltd Common Stock — how do they compare? Hims and Hers Health Inc trades at $27.52 (market cap $6.93B), while Dr. Reddy's Laboratories Ltd Common Stock trades at $12.75 (market cap $10.78B). The key difference: Dr. Reddy's Laboratories Ltd Common Stock is the larger of the two by market cap, and Dr. Reddy's Laboratories Ltd Common Stock pays a 0.65% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Dr. Reddy's Laboratories Ltd Common Stock for 0 Days on average.
| HIMS | RDY | |
|---|---|---|
Market Cap | $6.93B | $10.78B |
Volume | 9,771,956 | 2,724,343 |
Sector | Health | Health |
52-Week High | $62.76 | $15.38 |
52-Week Low | $14.52 | $11.38 |
Typical Hold Time | 21 Days | 0 Days |
Enterprise Value | $7.64B | $10.68B |
Dividend Yield | — | 0.65% |
Signals from Pluang's Aura AI — not financial advice
HIMS trades at $29.71, down 3.04% today, amid ongoing securities class action lawsuits. The stock shows bullish technical signals with strong moving average support and key resistance at $32. Fundamentally, while revenue grew to $2.35B in 2025, the company posted a net loss of -$142M in 2026 with negative profit margins, though it maintains a solid gross margin of 68.4%.
The investment outlook is mixed: technical indicators suggest near-term upside potential toward the $32.17 consensus target, but fundamental weakness and legal overhangs pose significant risks. Analyst sentiment leans cautious with 65% hold ratings, reflecting concerns about profitability and regulatory challenges despite growth prospects.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →Dr. Reddy's Laboratories Ltd. develops and manufactures generic medicines, active pharmaceutical ingredients (APIs), biosimilars, and over-the-counter (OTC) products, headquartered in Hyderabad, India, with therapeutic focus areas spanning gastrointestinal, cardiovascular, oncology, and dermatology.
Read more on RDY →